Tafamidis: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), CONITEC (Brazil) and DMC (Denmark), among others, recommended or restricted tafamidis, while AOTMIT (Poland), AWMSG (Wales) and NYE METODER (Norway), among others, did not recommend it.
PBAC (Australia) has been harder on tafamidis than on its own caseload: it refused 4 of 5 decisive submissions here (80%), against a base rate of 24% across everything it has assessed.
The file has been open for more than a decade: 14.2 years separate the first record, 1 May 2012 at AWMSG (Wales), from the most recent, 2026 at PBAC (Australia).
HIRA (South Korea) changed its position: not recommended on 6 Apr 2023, recommended by 10 Oct 2024, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for tafamidis.
The file is active: 11 of 28 records date from 2023 or later.
6 distinct indication wordings are recorded for tafamidis by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 28 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess tafamidis, on 1 May 2012; CONITEC (Brazil) did not open a file until 21 Jun 2024 — an unusually long tail of 12.1 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 8 years in total.
8 of the 16 agencies here assessed tafamidis more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
tafamidis has been through 16 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for tafamidis reads 12 not recommended, 11 recommended, 2 restricted and 1 other, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 23 Oct 2024 | Transthyretin amyloid kardiomyopati (ATTR-CM) | Anbefalet | source |
| CONITEC (Brazil) | 21 Jun 2024 | Tratamento da cardiomiopatia amiloide associada à transtirretina, do tipo selvagem ou hereditária, classes funcionais NY… | incorporated into SUS | source |
| NICE (England) | 19 Jun 2024 | NICE TA984 | recommended (optimised) | source |
| NYE METODER (Norway) | 16 Jun 2024 | Legemiddel til behandling av transtyretin amyloidose polynevropati | decision recorded | source |
| HIRA (South Korea) | 6 Apr 2023 | 정상형 또는 유전형 트랜스티레틴 아밀로이드성 심근병증 (ATTR-CM) | not reimbursed | source |
23 further decisions for tafamidis, across 14 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 19 further source documents.
Related molecules
- vutrisiran — divergent outcome (not recommended vs recommended) on a shared indication
- pitolisant — same ATC class N07X — Other nervous system
- fampridine — same ATC class N07X — Other nervous system
- omaveloxolone — same ATC class N07X — Other nervous system
- patisiran — same ATC class N07X — Other nervous system
- tofersen — same ATC class N07X — Other nervous system
Coverage: 28 decisions for tafamidis from 16 agencies, 2012 to 2026. Data to 7 Sep 2026. ATC class N07X — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.